Proactiveinvestors Australia

Admedus www.admedus.com/au/
Full Admedus profile here
Admedus Limited (ASX:AHZ), formerly Allied Healthcare Group is a diversified healthcare company focused on investing in next generation technologies, acquiring strategic assets to grow its product and service offerings and increasing sales revenue from its existing medical sales business.
Pdf

Allied Healthcare Group: Coridon’s Ian Frazer receives grant for HPV vaccine development

Thursday, December 20, 2012 by Angela Kean

A $200,000 grant from Australia’s National Health and Medical Research Council will assist in advancing the development of Professor Ian Frazer’s novel HPV vaccine, which will be used not only as a prevention of the disease, but also as a treatment. The commercial market for such a vaccine, if successful, is assessed at over $1.3B per annum.

A $200,000 grant from Australia’s National Health and Medical Research Council will assist in advancing the development of Professor Ian Frazer’s novel HPV vaccine, which will be used not only as a prevention of the disease, but also as a treatment. The commercial market for such a vaccine, if successful, is assessed at over $1.3B per annum.

Allied Healthcare Group’s (ASX: AHZ) investment company Coridon has gained A$200,000 in funding over the next two years to expand the scope of pre-clinical trials of a novel DNA vaccine for the prevention and treatment of human papilloma virus.

Professor Ian Frazer, and his team at the University of Queensland, has received the funding from Australia’s National Health and Medical Research Council.

HPV is one of the most common sexually transmitted diseases in the world and is the causing virus in around 5% of all cancer cases worldwide, particularly cervical cancer in women.

The commercial market for such a vaccine, if successful, is assessed at over $1.3 billion per annum, as it would be used to treat women with persistent cervical HPV infection.

Earlier work by Professor Frazer led to the development of the two currently available prophylactic vaccines, Gardasil® and Cervarix®, which are highly effective at stopping women not yet exposed to HPV from contracting the sexually transmitted infection.

A commercially available therapeutic HPV vaccine that would stop uninfected women from contracting HPV and also provide a therapeutic benefit to those already infected will have immense benefits to cervical cancer sufferers globally.

This condition affects about 2% of women during their lifetime, and currently requires lifetime follow up to prevent development of cervical cancer, but has no available therapy.

Gardasil® and Cervaix® are ineffective in preventing development of HPV-associated pre-malignancy if administered to people already infected with HPV.

Pre-clinical results released earlier this year by Allied, show the novel HPV vaccine successfully induces an immune response that can protect mice from developing cancer tumours associated with HPV infection.

Lee Rodne, managing director of Allied Healthcare Group, commented: “We welcome this contribution from the NHMRC which recognizes the important work being undertaken by Professor Frazer and his team at the University of Queensland.

“This novel HPV vaccine promises to be another major step forward in efforts to reduce the global burden of HPV-related disease, and the fight against cervical cancer.”


Large target market


Among HPV-associated cancers, cervical cancer is the second largest cause of cancer deaths in women worldwide and is primarily caused by HPV infection, with HPV DNA present in 99.7% of all cervical cancers.

Globally, this equates to 529,000 new cases per year, and about 275,000 deaths, with 86% of cases being in developing countries.

In the U.S., it is estimated that 26.8% of 14 to 59 year old females (around 20 million) are currently infected with HPV and another 6 million people become newly infected each year.

The U.S. National Institutes of Health stated that in 2009 there were 11,270 new cases and 4,070 deaths from cervical cancer in the U.S.

It is estimated that around $1.425 billion is spent in the U.S. each year to treat cervical cancers.


Coridon investment


Allied currently holds a 44.4% stake in Coridon, with plans to continue to increase its interest.

The company has exclusivity to increase to a 55% interest and then first right of refusal post-55% in Coridon’s vaccine programs.

Allied retains the ability to invest further in Coridon on the same terms established with the initial investment by Allied into Coridon in 2009.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Sign up to Proactive Investors

Andrew McCrea's Research Reports
Sign up to Andrew McCrea's Research Reports and Receive Latest Research & Flash Trades
Receive Proactive Investors Newsletter, Investor Forum Invites
Receive Proactive Investors Newsletter, Event Invites, Special Stock Notifications

Comments from Proactive Investors readers

  • Fill in your details below:
Verification Code
Andrew McCrea is Sub Authorised Representative (SAR: 291331) of Proactive Investors Australia Pty Ltd
(ABN: 19 132 787 654) which is a Corporate Auhorised Representative (CAR: 413802) of RM Capital
Pty Ltd (AFSL: 221938).

Copyright © proactiveinvestors.com.au, 2012. All Rights Reserved